56
Participants
Start Date
April 30, 2006
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
HER-2/neu intracellular domain protein
300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
flow cytometry
This is a laboratory test used to assess the antigen specific T cell population.
immunohistochemistry staining method
This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
biopsy
A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
Sterile water placement
100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
Tumor Vaccine Group at the University of Washington, Seattle
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle
National Cancer Institute (NCI)
NIH
University of Washington
OTHER